Provider: Wright Reports
Actelion Ltd: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Actelion Ltd Comments On FY 2012 Guidance-Reuters
Reuters reported that Actelion Ltd expects to return to profit in fiscal 2012 despite competition from rivals and pricing pressures and said key trial results for its new heart and lung drug would be ready in the second quarter. The group expects sales to fall in the low-to-mid single digit range on a local currency basis in fiscal 2012 after rising 5% in local currencies to CHF1.8 billion last year.
Latest Developments for Actelion Ltd
- Actelion Ltd Receives US FDA Approval Of Opsumit For The Treatment Of Pulmonary Arterial Hypertension
- Actelion Ltd Closes Acquisition Of Privately-held Ceptaris Therapeutics
- Actelion Ltd Raises FY 2013 EPS Guidance; Updates FY 2014 EPS Guidance; Lowers FY 2015 EPS Guidance-DJ
- Actelion Ltd Issues FY 2013 EPS Guidance Above Analysts' Estimates; Comments On FY 2014 And FY 2015 EPS Guidance-Conference Call
Latest Key Developments in Biotechnology
- BioSpecifics Technologies Corp announces FDA approval of XIAFLEX for treatment of peyronie's disease
- Xencor Inc announces closing of initial public offering
- Genmab reaches milestone from Janssen and raises FY 2013 financial guidance
- Genmab says milestone from Lundbeck puts revenue at top end of FY 2013 outlook range
- Share this
- Digg this